NA
REGN icon

Navellier & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Navellier & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,300
Closed -$390K – 351
2014
Q1 		$390K Sell
1,300
-1
-0.1% -$308 0.02% 214
2013
Q4 		$358K Buy
1,301
+95
+8% +$27.3K 0.02% 231
2013
Q3 		$377K Sell
1,206
-19
-2% -$5K 0.01% 212
2013
Q2 		$275K Buy
+1,225
New +$285K 0.01% 220

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Navellier & Associates's REGN Position: Q2 2014 in Review

Navellier & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q2 2014, closing a stake of 1,300 shares — an estimated $390K sold.

Navellier & Associates first reported a position in REGN in Q2 2013 and held it in 4 quarters. The position peaked at $390K in Q1 2014. 448 funds tracked by Wall St. Rank hold REGN as of Q2 2014.

  • Navellier & Associates reported no remaining Regeneron Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Navellier & Associates sold 1,300 Regeneron Pharmaceuticals shares in Q2 2014, an estimated $390K.
  • Navellier & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Navellier & Associates's Regeneron Pharmaceuticals position peaked at $390K in Q1 2014.
  • 448 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2014.

Based on Navellier & Associates's 13F filing for Q2 2014, filed 9 Jul 2014.